Actively Recruiting
Evaluating Amniotic Membrane Therapy Using Clarix FLO for Women with Interstitial CystitisPainful Bladder Syndrome A Randomized, Double-Blind Controlled Trial
Led by David Sheyn · Updated on 2026-09-04
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate amniotic membrane therapy for women with interstitial cystitispainful bladder syndrome ICPBS, a condition causing bladder and pelvic pain along with urinary urgency and frequency. The study focuses on the effectiveness of this therapy in improving symptoms, measured by validated questionnaires, in a randomized controlled trial setting. It addresses a significant need as current treatments vary widely and have variable success. Participants will receive either injections of micronized amniotic membrane Clarix FLO or a placebo saline injection into specific areas of the bladder muscle during cystoscopy under general anesthesia. The amniotic membrane product is a sterile, processed tissue from donated human placenta and umbilical cord. The study follows participants for 12 weeks after treatment with repeat clinical evaluations and symptom questionnaires. Throughout the 12-week period, participants will be monitored with symptom questionnaires at 2, 4, 8, and 12 weeks post-treatment. Additional urine cultures and bladder residual volume tests will be done at 2 and 4 weeks to check for urinary infections or retention. The main measurement is the change in the Interstitial Cystitis Symptom Index score, with safety and other symptom scales also assessed to understand the therapys impact and any adverse effects.
CONDITIONS
Brief Title
Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome
Research Team
D
Diana Mitchell, MD
D
David Sheyn, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here